Wegovy semaglutide tablets and the Wegovy injection contain the same active ingredient and lead to broadly similar weight loss. But they work differently in practice.
One is a once-weekly injection under the skin. The other is a daily tablet with specific fasting rules. The injection has been available in the UK since 2023, and the tablet received MHRA approval on 11 June 2026.
This guide compares the two on how they work, clinical trial results, side effects, dosing routine and practical fit, so you can make an informed decision about which might suit you.
Same medicine, two routines. The best choice is usually the one you can stick to week after week.
Same active ingredient, different delivery
Both Wegovy tablets and the Wegovy injection contain semaglutide, a GLP-1 receptor agonist. It mimics a hormone your gut releases naturally after you eat.
Semaglutide acts on receptors in your brain and gut to reduce your appetite, slow how quickly your stomach empties and dampen the "reward" you get from food. As a result, most people eat less without the constant hunger that makes dieting so hard.
How it works is identical. What differs is how semaglutide gets into your bloodstream, how often you take it and what each one asks of your routine.
How do the two forms differ?
Wegovy injection
The injection delivers semaglutide just under the skin of your tummy, thigh or upper arm, using a pre-filled pen. You take it once a week, and it's absorbed reliably, with less day-to-day variation in your blood levels.
There's no fasting before or after the injection, and no food or drink rules around your dose.
The dose goes up over 16 to 20 weeks, starting at 0.25mg a week and rising to a maintenance dose of 2.4mg a week. A higher 7.2mg weekly dose was approved by the MHRA in 2026 for people who need it.1
Wegovy tablets
Taking semaglutide by mouth is trickier than injecting it, because the protein would normally be broken down in your stomach before it could be absorbed.
To get around this, the tablet contains a compound called SNAC (salcaprozate sodium). It temporarily makes your stomach lining more permeable, so semaglutide can pass into your bloodstream.2
Even with SNAC, only a very small fraction of each dose reaches your bloodstream. That's why the tablet dose is much higher than the injection: 25mg a day, compared with 2.4mg a week.
You take the tablet once a day on an empty stomach, with no more than 120ml of plain water. Then you wait at least 30 minutes before eating, drinking anything other than water or taking other medicines.3 Food in your stomach significantly reduces how much semaglutide is absorbed.
For Wegovy tablets, fasting is essential to get the full effect.
That 30-minute morning window is the biggest practical difference between the two. For some people, it fits naturally into their morning. For others, it's a daily constraint the injection doesn't have.
For the full routine and titration schedule, see our Wegovy tablet dosage guide.
What do the clinical trials show?
The two forms of Wegovy have been studied in separate trial programmes: the STEP trials for the injection, and the OASIS trials for the tablet.
Injection: STEP 1 trial
The STEP 1 trial, published in the New England Journal of Medicine in 2021, involved 1,961 adults with obesity, or overweight with at least one weight-related health condition.
People taking semaglutide 2.4mg injections once a week for 68 weeks lost an average of 14.9% of their starting weight, compared with 2.4% on placebo. Around 86% lost at least 5% of their body weight, and around half lost 15% or more.4
Tablet: OASIS 4 trial
The OASIS 4 trial, published in the New England Journal of Medicine in September 2025, studied oral semaglutide 25mg once a day in 307 adults with obesity or overweight.
Over 64 weeks, people lost an average of 13.6% of their starting weight, compared with 2.2% on placebo. Among those who stuck fully with treatment, the average reached 16.6%. Around 3 in 10 people on the tablet lost 20% or more of their body weight.5
Analyses presented at ObesityWeek 2025 found that oral and injected semaglutide gave similar results for weight loss and other health markers, including blood pressure, blood sugar and cholesterol.
Comparing the two
The two trials weren't designed to compare the forms directly, and they used different designs and lengths (68 weeks for STEP 1, 64 weeks for OASIS 4). So small differences in the averages shouldn't be over-read.
Both forms lead to clinically significant weight loss of around 13 to 17%, and both far outperform placebo. For most people, the difference in average results is unlikely to be the deciding factor. What matters more is which one you can use consistently over the long term.
Around 13 to 17% average weight loss with either form. Consistency matters more than the format.
Side effects: are they the same?
Both forms contain semaglutide, so their side effects are broadly similar. The most commonly reported in both the STEP and OASIS trials are nausea, diarrhoea, vomiting, constipation and tummy discomfort.
Most digestive symptoms are mild to moderate. They tend to happen while your dose is going up, and settle as your body adjusts.5
There are two meaningful differences between them:
- Injection site reactions - redness, bruising or irritation where you inject only happen with the pen. They're uncommon.
- Vomiting - this was reported slightly more often with the tablet at its full dose in trials, and variable absorption may mean some people feel more nauseous on certain days.
Your prescriber will check your medical history before you start either one. Tell them if you've had pancreatitis, or if you or a family member has had a rare thyroid cancer (medullary thyroid carcinoma) or multiple endocrine neoplasia type 2.
Severe stomach pain that spreads to your back? Get urgent medical help, as it can be a sign of pancreatitis.
UK availability in 2026
The Wegovy injection is available on private prescription in the UK. The standard 2.4mg dose has been available since 2023, and the MHRA approved a 7.2mg single-dose pen in April 2026 for people who need the higher maintenance dose.1
Wegovy semaglutide tablets were approved by the MHRA on 11 June 2026, making the UK the first country in Europe to license an oral GLP-1 for weight management. NHS access through NICE is unlikely before 2027.
Both Wegovy injection and tablets are now available in the UK.
The approved use covers adults with obesity (BMI of 30 or above), or overweight (BMI of 27 to 30) with at least one weight-related health condition, alongside a reduced-calorie diet and more physical activity. Those are the same criteria as the Wegovy injection.
Rybelsus is also an oral semaglutide licensed in the UK, but only for type 2 diabetes. Wegovy tablets are the first oral semaglutide approved for weight management in the UK.
The MHRA has confirmed that people currently treated privately with the 2.4mg weekly injection can move straight to the 25mg daily tablet, without starting the titration again.
Which option is right for you?
The injection and the tablet aren't really competing treatments. They're two routes to the same outcome, and the right choice depends on practical fit, not which is clinically better.
The injection may suit you better if you'd prefer a once-a-week routine with no daily food rules.
The tablet may be worth considering if you really don't like needles or would prefer a daily tablet, and you're happy to plan around the morning fasting rule. It gives people who've avoided injections a licensed alternative.
It's also worth knowing that sticking with treatment is likely to matter more for your results than which form you choose. A treatment you take reliably every day or week will beat one you find hard to keep up, whatever the trial averages say.
Not sure which suits your lifestyle? Speak to a prescriber, who can take your full medical history and preferences into account.
The Wegovy injection is available on Pharmica after a short consultation. For the latest on the tablets, visit the Wegovy tablets page.
When to seek further advice
Contact your GP or prescribing clinician if you:
- Experience severe or persistent nausea, vomiting, or upper abdominal pain that does not resolve
- Develop symptoms consistent with pancreatitis: severe upper abdominal pain that radiates to the back, particularly after eating
- Notice any lump or swelling in the neck, or have difficulty swallowing or breathing
- Are taking other medications and want to confirm whether timing adjustments are needed
A full list of known side effects and drug interactions is available in the patient information leaflet supplied with your medication. If you have any concerns about your treatment, speak to your prescribing pharmacist or GP.
Frequently asked questions
Is the Wegovy tablet available in the UK?
Not just yet. But Wegovy semaglutide tablets were approved by the MHRA on 11 June 2026. Novo Nordisk expects private prescription availability to follow within weeks. The Wegovy injection also remains available in the UK now.
Do Wegovy semaglutide tablets produce the same weight loss as the injection?
The results are comparable. In the OASIS 4 trial, people taking Wegovy semaglutide tablets 25mg once daily lost an average of 13.6% of their body weight over 64 weeks, with full-adherence participants averaging 16.6%. The STEP 1 trial for the injection produced 14.9% average weight loss over 68 weeks. Both forms far outperform placebo, and the practical gap between them is small.
Why is the dose of the tablet so much higher than the injection?
Because far less of an oral dose reaches the bloodstream. Semaglutide taken by mouth is largely broken down in the stomach before it can be absorbed. The tablet uses a compound called SNAC to help semaglutide pass through the stomach lining, but even so, only a small fraction of each dose gets through. A 25mg daily tablet is needed to achieve blood levels roughly equivalent to those produced by a 2.4mg weekly injection.
Do you have to fast before taking Wegovy semaglutide tablets?
Yes. The tablet must be taken on an empty stomach with no more than 120ml of plain water, and you must wait at least 30 minutes before eating, drinking anything other than water, or taking other medications. Food significantly reduces absorption. This is the most important daily requirement of the tablet that the injection does not share.
Are the side effects of the tablet and injection the same?
Broadly yes. Both forms most commonly cause nausea, diarrhoea, vomiting, constipation, and abdominal discomfort, particularly during dose escalation. Two differences stand out: injection-site reactions only occur with the pen, and vomiting was reported slightly more often with the tablet at full dose in clinical trials. The overall safety profile of both forms is consistent with the GLP-1 class of medicines.
Can you switch from the Wegovy injection to the tablet?
Yes. Now that Wegovy semaglutide tablets have MHRA approval, switching from the injection is a straightforward option under your prescriber's guidance. For the full process, including equivalent starting doses, see our guide on how to switch from Wegovy injections to tablets.
Is Rybelsus the same as the Wegovy tablet?
Both contain semaglutide as the active ingredient, but they are different products. Rybelsus is a lower-dose oral semaglutide tablet (up to 14mg) licensed in the UK for type 2 diabetes, not for weight loss. Wegovy semaglutide tablets contain a higher dose (25mg) formulated specifically for weight management. Rybelsus is not a substitute for Wegovy semaglutide tablets and should not be used off-label for weight loss.
References
- Medicines and Healthcare products Regulatory Agency. Single-dose 7.2mg semaglutide (Wegovy) pen approved to treat adult patients with obesity. GOV.UK; April 2026. gov.uk/mhra
- Buckley ST, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018;10(467):eaar7047. doi:10.1126/scitranslmed.aar7047
- DailyMed. Wegovy (semaglutide) tablets 25mg: Prescribing Information. US National Library of Medicine. dailymed.nlm.nih.gov
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- Wharton S, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. New England Journal of Medicine. 2025;393(11):1077-1087. doi:10.1056/NEJMoa2500969
This article is intended for informational purposes only and does not replace professional medical advice. Always read the patient information leaflet supplied with your medication and speak to a healthcare professional if you have specific concerns about your treatment.